<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hd-l2" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hd-l2</book-part-id>
      <title-group>
        <title>Huntington Disease-Like 2</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Margolis</surname>
            <given-names>Russell L</given-names>
          </name>
          <degrees>MD</degrees>
          <email>rmargoli@jhmi.edu</email>
          <aff>Professor of Psychiatry and Neurology, Laboratory of Genetic Neurobiology <break/>Department of Psychiatry <break/>Johns Hopkins University School of Medicine<break/>Baltimore, Maryland</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2004-01-30" date-type="created">
          <day>30</day>
          <month>1</month>
          <year>2004</year>
        </date>
        <date iso-8601-date="2012-04-26" date-type="updated">
          <day>26</day>
          <month>4</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="huntington" document-type="chapter">Huntington Disease</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="hgps" document-type="chapter">Hutchinson-Gilford Progeria Syndrome</related-object>
      <abstract id="hd-l2.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Huntington disease-like 2 (HDL2) typically presents in midlife with a relentless progressive triad of movement, emotional, and cognitive abnormalities progressing to death over ten to 20 years. In some individuals the presentation resembles juvenile-onset Huntington disease (HD) or the Westphal variant of HD, usually presenting in the fourth decade (ages 29 to 41 years) with diminished coordination and weight loss despite increase in food intake. Neurologic abnormalities include parkinsonism (rigidity, bradykinesia, tremor), dysarthria, and hyperreflexia. In others the presentation is more variable but, in general, corresponds to typical HD. </p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of HDL2 requires molecular genetic testing of <italic toggle="yes">JPH3</italic>, the only gene in which mutation is known to cause HDL2. In the presence of a clinical syndrome consistent with HDL2 (findings and family history typical of Huntington disease), 41 or more CTG trinucleotide repeats in <italic toggle="yes">JPH3</italic> are considered diagnostic of HDL2.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment is symptomatic and is presumably similar to that for HD and other neurodegenerative disorders, though this must be considered speculative pending objective data. Pharmacologic agents that may suppress abnormal movements include low-dose neuroleptic agents such as fluphenazine and haloperidol, and potentially tetrabenazine. Antidepressants, antipsychotics, mood stabilizers (lithium, valproic acid, carbamazepine, and lamotragine), and occasionally stimulants may treat psychiatric manifestations. Education about the course of disease and environmental interventions (regular schedules, use of lists to assist memory, removing clutter so that things are easier to find) benefit affected individuals and family members. </p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Remove loose rugs and clutter from the individual's home to help prevent falls and other injuries; driving may need to be curtailed or limited to prevent risk of accidents; food should be prepared in such a manner as to prevent choking.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitor nutrition and swallowing in order to implement feeding changes when necessary to minimize risk of aspiration; gait should be monitored, with use of appropriate strategies or devices to minimize falls; monitor driving to assure that the affected individual does not present a danger to themselves or others; monitor mood and irritability, such that measures to decrease the risk of suicide, other behavioral abnormalities, and distress may be implemented.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Any agents that increase ataxia should be used with caution; avoid polypharmacy, which may exacerbate delirium.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>HDL2 is inherited in an autosomal dominant manner. HDL2 resulting from <italic toggle="yes">de novo</italic> mutation has not been reported. If a parent of the proband is affected or has the <italic toggle="yes">JPH3</italic> expansion, the risk to each sib of a proband is 50%. Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant in the family has been identified. </p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hd-l2.Diagnosis">
        <title>Diagnosis</title>
        <sec id="hd-l2.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of Huntington disease-like 2 (HDL2) is usually suspected in individuals who present with findings typical of <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object> (HD) and a family history of an HD-like disorder, but who do not have a disease-causing CAG expansion (i.e., reduced-penetrance allele or full-penetrance allele) in <italic toggle="yes">HTT</italic>. </p>
          <p>Clinical findings are not sufficient to establish the diagnosis of HDL2: molecular genetic testing is required.</p>
        </sec>
        <sec id="hd-l2.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">JPH3</italic> is the only gene in which mutation is known to cause Huntington disease-like 2 (HDL2).</p>
          <p>
            <bold>Allele sizes</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Normal alleles.</bold> Six to 28 CTG repeats [<xref ref-type="bibr" rid="hd-l2.REF.holmes.2001.377">Holmes et al 2001</xref>]. The diagnosis can be excluded if neither allele has a repeat length greater than 28 CTG repeats.</p>
            </list-item>
            <list-item>
              <p><bold>Alleles of questionable significance.</bold> 29 to 39 CTG repeats; the pathogenicity of alleles in this range is unknown. Repeats in this range could be either of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>Mutable normal alleles</bold> that do not have a phenotypic effect in the individual but are unstable in vertical transmissionNote: (1) A 48-year-old woman with an atypical cerebellar disorder (rapid onset following hospitalization for out-of-control diabetes mellitus, little or no progression) had a <italic toggle="yes">JPH3</italic> CTG repeat length of 33 in one allele. Her 30-year-old son had developed Cogan's syndrome, an autoimmune disease resulting in complete hearing loss, at age 25 years. He complained of tinnitus, occasional lapses of concentration, and difficulty with balance, all associated with the onset of Cogan's syndrome. Examination suggested possible cerebellar involvement. He had a CTG repeat length of 35, suggesting repeat length instability at this range. (2) An individual with molecularly diagnosed Huntington disease coincidentally also had a <italic toggle="yes">JPH3</italic> allele of 34 CTG repeats [Author, personal observation].</p>
                </list-item>
                <list-item>
                  <p><bold>Reduced-penetrance alleles</bold> that result in very late-onset disease and/or a different phenotype and/or no occurrence of clinical disease in a normal life span</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Full-penetrance (disease-causing) alleles.</bold> 41 CTG repeats or greater. In the presence of a clinical syndrome consistent with HDL2, an allele with 41 or more CTG repeats is considered diagnostic of HDL2. The longest repeat expansion detected so far is 58 triplets. Note: Apparently unaffected individuals with repeat lengths in the pathogenic range may eventually develop the disease. One individual (in a family with a proband with clinically, neuropathologically, and molecularly defined HDL2) had an expanded allele of 44 CTG repeats without clear evidence of clinical HDL2 at age 65 years. It is possible that the effects of a mild stroke several years prior to examination masked signs of HDL2.</p>
            </list-item>
          </list>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Targeted mutation analysis.</bold> A PCR assay determines within one to two repeats the length of the CTG trinucleotide repeat in <italic toggle="yes">JPH3</italic>. </p>
            </list-item>
          </list>
          <table-wrap id="hd-l2.T.summary_of_molecular_genetic_tes" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Huntington Disease-Like 2</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutations Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">JPH3</italic>
                  </td>
                  <td headers="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted mutation analysis</td>
                  <td headers="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">CTG repeat expansion </td>
                  <td headers="hd_h_hd-l2.T.summary_of_molecular_genetic_tes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Nearly 100%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="hd-l2.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="hd-l2" object-id="hd-l2.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. </p>
              </fn>
              <fn id="hd-l2.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="hd-l2.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="hd-l2.TF.1.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a mutation that is present in the indicated gene</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Interpretation of test results.</bold> The test should detect nearly all expanded alleles; however, it is theoretically possible that expanded repeats may not be detected because of a polymorphism at the primer site or an unusually long repeat.</p>
        </sec>
        <sec id="hd-l2.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>Confirming/establishing the diagnosis in a proband</bold> requires molecular genetic testing.</p>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior confirmation of the diagnosis of HDL2 through identification of a disease-causing <italic toggle="yes">JPH3</italic> expansion in the family. </p>
          <list list-type="bullet">
            <list-item>
              <p>If genetic confirmation of the diagnosis is not available, a negative HDL2 test in the asymptomatic adult may mean that the familial disease is not HDL2.</p>
            </list-item>
            <list-item>
              <p>A positive test in the asymptomatic adult, however, would still be predictive.</p>
            </list-item>
          </list>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family. </p>
        </sec>
      </sec>
      <sec id="hd-l2.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hd-l2.Clinical_Description">
          <title>Clinical Description</title>
          <p>Like <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object> [<xref ref-type="bibr" rid="hd-l2.REF.ross.1997.305">Ross et al 1997</xref>, <xref ref-type="bibr" rid="hd-l2.REF.bates.2002">Bates et al 2002</xref>], HDL2 typically presents in midlife with a relentless progressive triad of movement, emotional, and cognitive abnormalities progressing to death over ten to 20 years.</p>
          <p>The course of HDL2 appears to fall into two presentations that probably reflect opposite ends of a spectrum [<xref ref-type="bibr" rid="hd-l2.REF.holmes.2001.377">Holmes et al 2001</xref>, <xref ref-type="bibr" rid="hd-l2.REF.margolis.2001.373">Margolis et al 2001</xref>, <xref ref-type="bibr" rid="hd-l2.REF.walker.2002.1031">Walker et al 2002</xref>, <xref ref-type="bibr" rid="hd-l2.REF.stevanin.2003.1599">Stevanin et al 2003</xref>, <xref ref-type="bibr" rid="hd-l2.REF.walker.2003a.1527">Walker et al 2003a</xref>, <xref ref-type="bibr" rid="hd-l2.REF.walker.2003b.1002">Walker et al 2003b</xref>, <xref ref-type="bibr" rid="hd-l2.REF.margolis.2004.670">Margolis et al 2004</xref>]. The two presentations are: (1) weight loss and poor coordination, with fairly rapid development of rigidity and dystonia; and (2) chorea with a somewhat less rapidly progressive course. This phenotypic range may broaden as additional individuals with HDL2 are identified. </p>
          <p>The first HDL2 presentation, similar to juvenile-onset Huntington disease (HD) or the Westphal variant of HD, was observed in the index family, which with its many branches and suspected branches accounts for a sizeable proportion of cases outside of South Africa [<xref ref-type="bibr" rid="hd-l2.REF.krause.2002.528s">Krause et al 2002</xref>]. Onset is usually from age 29 to 41 years with diminished coordination and weight loss, which is often striking despite an increase in food intake. The disorder culminates in a bedridden, nonverbal state with profound dementia ten to 15 years after onset. </p>
          <p>Neurologic abnormalities include: rigidity, bradykinesia, tremor, dysarthria, and hyperreflexia with no clear cerebellar signs and little or no clinically detectable abnormalities of eye movements. Although dystonia and chorea occur in a majority of individuals, the chorea may be mild. Dementia and psychiatric disturbances are universal. Depression, apathy, and irritability are the most common forms of psychiatric disturbance. Death usually follows ten to 20 years after disease onset.</p>
          <p>The second presentation is more variable but, in general, corresponds to typical HD. Onset is generally in the fifth decade and beyond. Chorea is more prominent and abnormal eye movements (jerky saccades) may be present, while dystonia, bradykinesia, tremor, hyperreflexia, and dysarthria are less prominent. Psychiatric and cognitive disturbances may be milder, and the disease progresses more slowly.</p>
          <p><bold>Acanthocytosis</bold> has been reported in affected members of one family with HDL2 and in some affected members of a second family. The significance of acanthocytosis remains uncertain [<xref ref-type="bibr" rid="hd-l2.REF.walker.2002.1031">Walker et al 2002</xref>, <xref ref-type="bibr" rid="hd-l2.REF.walker.2003b.1002">Walker et al 2003b</xref>]. </p>
          <p><bold>Brain MRI</bold> shows the typical features of HD: prominent atrophy of the caudate and cerebral cortex with sparing of the brain stem and cerebellum [<xref ref-type="bibr" rid="hd-l2.REF.margolis.2001.373">Margolis et al 2001</xref>]. Findings may be quite modest early in the clinical course of the disease.</p>
          <p><bold>Neuropathology.</bold> Neuronal loss is most prominent in the striatum and the cerebral cortex. Striatal loss appears limited to medium spiny neurons and occurs in a dorsal to ventral gradient as in HD. Intranuclear inclusions that stain with antibodies against polyglutamine, ubiquitin [<xref ref-type="bibr" rid="hd-l2.REF.margolis.2001.373">Margolis et al 2001</xref>, <xref ref-type="bibr" rid="hd-l2.REF.walker.2002.1031">Walker et al 2002</xref>], torsinA [<xref ref-type="bibr" rid="hd-l2.REF.walker.2002.1031">Walker et al 2002</xref>], and TBP have been detected, predominantly in the cortex [<xref ref-type="bibr" rid="hd-l2.REF.rudnicki.2008.366">Rudnicki et al 2008</xref>].</p>
        </sec>
        <sec id="hd-l2.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Longer CTG repeat length correlates with an earlier age of onset, with a relationship similar to that observed in <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object> [<xref ref-type="bibr" rid="hd-l2.REF.margolis.2004.670">Margolis et al 2004</xref>]. It is possible that longer repeat length (~50 CTG repeats or longer) may be associated with the more virulent course observed in the first subtype of HDL2. However, this association is derived primarily from the large index family [<xref ref-type="bibr" rid="hd-l2.REF.margolis.2001.373">Margolis et al 2001</xref>] and could alternatively be explained by other genetic or environmental factors. Thus, until further data have been collected, caution must be employed in interpreting the clinical implications of a CTG repeat expansion of a given length. Disease course in the other family members of the individual requesting information may be valuable as a clinical guide in the interim.</p>
        </sec>
        <sec id="hd-l2.Penetrance">
          <title>Penetrance</title>
          <p>For ethical reasons, only a few unaffected individuals from families with HDL2 have been tested; therefore, the penetrance is unknown. </p>
        </sec>
        <sec id="hd-l2.Anticipation">
          <title>Anticipation</title>
          <p>Limited evidence from the large index pedigree suggests that anticipation may occur [<xref ref-type="bibr" rid="hd-l2.REF.margolis.2001.373">Margolis et al 2001</xref>]. </p>
        </sec>
        <sec id="hd-l2.Nomenclature">
          <title>Nomenclature</title>
          <p>The disease is occasionally (and incorrectly) referred to as HD2.</p>
        </sec>
        <sec id="hd-l2.Prevalence">
          <title>Prevalence</title>
          <p>HDL2 is rare. Information about HDL2 is limited by the small number of affected individuals so far identified (fewer than 25 pedigrees and 40 affected individuals). </p>
          <p>Most individuals with HDL2 have been of definite or likely African ancestry, including a Mexican family (from a region originally colonized by survivors of a wrecked African slave ship), and five unrelated cases detected in Brazil. HDL2 has also been found in an individual from Morocco [<xref ref-type="bibr" rid="hd-l2.REF.holmes.2001.377">Holmes et al 2001</xref>] and an individual identified as being of Mid-Eastern origin [<xref ref-type="bibr" rid="hd-l2.REF.wild.2007.681">Wild &#x00026; Tabrizi 2007</xref>].</p>
          <p>In South Africa, individuals of African ethnicity with an HD-like phenotype are almost as likely to have HDL2 as HD [<xref ref-type="bibr" rid="hd-l2.REF.krause.2002.528s">Krause et al 2002</xref>].</p>
          <p>Outside of South Africa, HDL2 has been identified in as few as 1% of individuals with clinically or pathologically defined HD who do not have an <italic toggle="yes">HTT</italic> pathogenic variant [<xref ref-type="bibr" rid="hd-l2.REF.rosenblatt.1998.215">Rosenblatt et al 1998</xref>, <xref ref-type="bibr" rid="hd-l2.REF.stevanin.2003.1599">Stevanin et al 2003</xref>, <xref ref-type="bibr" rid="hd-l2.REF.margolis.2004.670">Margolis et al 2004</xref>]. In Brazil, where an estimated 44% of the population is of African descent, as many as 10% of cases with an HD-like disorder may have HDL2 [<xref ref-type="bibr" rid="hd-l2.REF.rodrigues.2011.419">Rodrigues et al 2011</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Two individuals with HDL2 were detected out of 300 individuals referred to a large commercial diagnostic laboratory in the United States for HD testing. None of the 300 individuals showed evidence of an <italic toggle="yes">HTT</italic> disease-causing gene expansion.</p>
            </list-item>
            <list-item>
              <p>In 74 individuals (60 of French origin) with a variety of movement disorders with and without dementia, and an autosomal dominant inheritance pattern in 36% [<xref ref-type="bibr" rid="hd-l2.REF.stevanin.2002.965">Stevanin et al 2002</xref>], only one case of HDL2 was detected (in an individual from North Africa).</p>
            </list-item>
            <list-item>
              <p>In 1600 individuals who had no evidence of an <italic toggle="yes">HTT</italic> pathogenic variant (including 147 individuals with a family history of chorea) referred by neurologists in Germany and Austria, no <italic toggle="yes">JPH3</italic> expansions were found [<xref ref-type="bibr" rid="hd-l2.REF.bauer.2002.662">Bauer et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>If the cases under consideration are narrowly defined, the frequency of HDL2 is much higher. For instance, of four individuals identified by <xref ref-type="bibr" rid="hd-l2.REF.rosenblatt.1998.215">Rosenblatt et al [1998]</xref> with HD-like autosomal dominant disorders, two ultimately proved to have HDL2.</p>
            </list-item>
            <list-item>
              <p>No cases of HDL2 have yet been detected in Japan, though only a small number of individuals have been tested. </p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="hd-l2.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Mutation of <italic toggle="yes">JPH3</italic> has not been associated with other phenotypes. </p>
      </sec>
      <sec id="hd-l2.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of Huntington disease-like 2 (HDL2) is the same as for <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object> (HD), and is based on the co-occurrence of: (1) movement abnormalities (chorea, dystonia, and/or parkinsonism) reflecting basal ganglia dysfunction, dementia, and psychiatric disturbances; and (2) autosomal dominant inheritance. </p>
        <p>The most obvious diagnosis to exclude is HD itself. Also to be considered is <related-object link-type="booklink" source-id="gene" document-id="neuroferritin" document-type="chapter">neuroferritinopathy</related-object> (ferritin-associated basal ganglia disease).</p>
        <p>Other possibilities:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="drpla" document-type="chapter">Dentatorubral-pallidoluysian atrophy</related-object> (DRPLA) (more common in Japan)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="chac" document-type="chapter">Chorea-acanthocytosis</related-object> (both autosomal dominant and autosomal recessive forms)</p>
          </list-item>
          <list-item>
            <p>Benign hereditary chorea (usually of childhood onset)</p>
          </list-item>
          <list-item>
            <p>Certain autosomal dominant spinocerebellar ataxias (particularly <related-object link-type="booklink" source-id="gene" document-id="sca2" document-type="chapter">SCA2</related-object>, <related-object link-type="booklink" source-id="gene" document-id="sca3" document-type="chapter">SCA3</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="sca17" document-type="chapter">SCA17</related-object>)</p>
          </list-item>
          <list-item>
            <p>Hereditary forms of Creutzfeld-Jakob disease (see <related-object link-type="booklink" source-id="gene" document-id="prion" document-type="chapter">Genetic Prion Diseases</related-object>)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object> (exclusion is essential since Wilson disease is treatable)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="ncl" document-type="chapter">Neuronal ceroid-lipofuscinoses</related-object> (usually autosomal recessive childhood onset, rarely dominant with adult onset)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">Pantothenate kinase-associated neurodegeneration</related-object> (PKAN) (childhood onset, autosomal recessive)</p>
          </list-item>
          <list-item>
            <p>Fahr disease (<related-object link-type="booklink" source-id="gene" document-id="bgc" document-type="chapter">familial idiopathic basal ganglia calcification</related-object>)</p>
          </list-item>
          <list-item>
            <p>Mitochondrial diseases (see <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disease Overview</related-object>) (maternal inheritance)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="mcleod" document-type="chapter">McLeod neuroacanthocytosis syndrome</related-object> (X-linked neuroacanthocytosis)</p>
          </list-item>
        </list>
        <p>Nonfamilial disorders that may present like HDL2 include: tardive dyskinesia (common), Sydenham's chorea, systemic lupus erythematosus (SLE), neurosyphilis, hyperglycemia, acquired forms of Creutzfeld-Jakob disease, pregnancy, multisystem atrophy, and thyroid disease.</p>
        <p>HD-like symptoms can also arise from drugs, including: antipsychotics, anticonvulsants, oral contraceptives, lithium, and stimulants.</p>
        <p>A variety of parkinsonian conditions may also be considered, including: <related-object link-type="booklink" source-id="gene" document-id="parkinson-overview" document-type="chapter">Parkinson disease</related-object>, progressive supranuclear palsy, corticobasal ganglia degeneration, <related-object link-type="booklink" source-id="gene" document-id="drd" document-type="chapter">dopa-responsive dystonia</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="ftdp-17" document-type="chapter">frontotemporal dementia with parkinsonism-17</related-object>.</p>
      </sec>
      <sec id="hd-l2.Management_1">
        <title>Management</title>
        <sec id="hd-l2.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with Huntington disease-like 2 (HDL2), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neuroimaging studies to exclude other lesions, such as subdural hematomas secondary to falls, which may be contributing to signs or symptoms</p>
            </list-item>
            <list-item>
              <p>Standardized rating instruments, such as the Unified Huntington's Disease Rating Scale (UHDRS) or Quantitated Neurological Examination (QNE) for motor abnormalities and the Mini-Mental State Examination (MMSE) for cognition</p>
            </list-item>
            <list-item>
              <p>Genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="hd-l2.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment is symptomatic and based on the treatment for HD and other neurodegenerative disorders.</p>
          <list list-type="bullet">
            <list-item>
              <p>Pharmacologic agents may suppress abnormal movements. The most common choices are low-dose neuroleptic agents, such as fluphenazine or haloperidol.</p>
            </list-item>
            <list-item>
              <p>Tremor in one individual was suppressed with clonazepam. However, clonazepam, levodopa/carbidopa, anticholinergics, and typical and atypical neuroleptics were not found helpful in treating the abnormal movements of other affected individuals.</p>
            </list-item>
            <list-item>
              <p>Based on experience with <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object>, antidepressants, antipsychotics, mood stabilizers (lithium, valproic acid, carbamazepine, and lamotragine), and occasionally stimulants may be effective in treating the psychiatric manifestations of HDL2.</p>
            </list-item>
            <list-item>
              <p>In the only report specifically related to HDL2, depression partially responded to sertaline in one individual and to nortriptyline in another individual [<xref ref-type="bibr" rid="hd-l2.REF.walker.2003b.1002">Walker et al 2003b</xref>].</p>
            </list-item>
            <list-item>
              <p>The affected individual, other family members, and care providers should be educated regarding the likely course of the disease. Assurance that cognitive decline, depression, apathy, and irritability are manifestations of the disease rather than the "fault" of the individual can decrease stress and guilt.</p>
            </list-item>
            <list-item>
              <p>Environmental interventions (establishing regular schedules, easing of expectations to maintain the family finances, encouraging the use of lists to assist with memory) may help.</p>
            </list-item>
            <list-item>
              <p>Families often need help in obtaining social services (see <xref ref-type="sec" rid="hd-l2.Resources">Resources</xref>). </p>
            </list-item>
          </list>
        </sec>
        <sec id="hd-l2.Prevention_of_Primary_Manifestatio">
          <title>Prevention of Primary Manifestations</title>
          <p>No known treatment stops or slows the progression of HDL2.</p>
        </sec>
        <sec id="hd-l2.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>Loose rugs and clutter should be removed from the individual's home to help prevent falls and other injuries. Driving may need to be curtailed or limited to prevent risk of accidents. Food preparation may need to be altered to prevent choking. </p>
        </sec>
        <sec id="hd-l2.Surveillance">
          <title>Surveillance </title>
          <p>Nutrition and swallowing should be monitored. Feeding changes should be implemented when necessary to minimize the risk of aspiration. </p>
          <p>Gait should be monitored, with consultation as needed from physical therapists to provide the most appropriate strategies or devices to minimize falls. </p>
          <p>Driving safety should be monitored, with consideration of formal driving safety evaluations if safety is uncertain. </p>
          <p>Monitor mood and irritability so that measures to decrease the risk of suicide, other behavioral abnormalities, and distress may be implemented.</p>
        </sec>
        <sec id="hd-l2.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Any agents that increase ataxia should be used with caution.</p>
          <p>Individuals with HDL2, like others with neurodegenerative disorders, are vulnerable to delirium from medical illnesses and medicines, especially polypharmacy.</p>
        </sec>
        <sec id="hd-l2.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="hd-l2.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hd-l2.Pregnancy_Management">
          <title>Pregnancy Management </title>
          <p>There is no specific information available about disease management during pregnancy. Prudence suggests close attention to prevention of falls and monitoring for swallowing difficulties. Medications should be reviewed to assess their safety during pregnancy. </p>
        </sec>
        <sec id="hd-l2.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="hd-l2.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hd-l2.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Huntington disease-like 2 is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="hd-l2.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals with HDL2 have an affected parent.</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">De novo</italic> mutation has not been reporeted as a cause of HDL2, but family information is lacking in several cases. </p>
            </list-item>
            <list-item>
              <p>It is possible that CTG repeat expansion of a mutable normal allele/reduced-penetrance allele into the affected range may occur, as it does in HD; such an event has never been documented. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer molecular genetic testing to an asymptomatic parent.</p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with HDL2 have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected or has the <italic toggle="yes">JPH3</italic> expansion, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>It is conceivable that an affected parent with a repeat length just at the disease threshold could transmit an expanded allele to one sib and an unexpanded allele to another sib; such a case has not yet been detected.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with HDL2 has a 50% chance of inheriting the pathogenic variant.</p>
          <p>
            <bold>Other family members of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the genetic status of the proband's parents. </p>
            </list-item>
            <list-item>
              <p>If a parent is affected or has the <italic toggle="yes">JPH3</italic> expansion, his or her family members are at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="hd-l2.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Considerations in families with apparent <italic toggle="yes">de novo</italic> mutation.</bold> When neither parent of a proband with an autosomal dominant condition has the disease-causing expansion, it is possible that the proband has a <italic toggle="yes">de novo</italic> mutation. Alternative explanations include alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption.</p>
          <p><bold>Testing of at-risk asymptomatic adults.</bold> Testing for the expansion in the absence of definite symptoms of the disease is predictive testing. Testing of at-risk asymptomatic adults for Huntington disease-like 2 is possible using the techniques described in <xref ref-type="sec" rid="hd-l2.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>. When testing at-risk individuals for HDL2, an affected family member should be tested first to confirm the molecular diagnosis in the family.</p>
          <p>Whether an asymptomatic adult will develop HDL2 can be predicted by the length of the repeat in <italic toggle="yes">JPH3</italic>, although this prediction must be qualified by the fact that the correlation between repeat length and disease has been examined in relatively few individuals. In particular, the penetrance of repeat lengths near the disease threshold and the association between age of onset and repeat length have not been well established. As additional persons with HDL2 are reported, the reliability of clinical predictions based on the length of the HDL2-causing expansion will increase. One approach could be to assign at-risk individuals with an expansion of 41 or more triplets a status of "high probability."</p>
          <p>At-risk, asymptomatic, adult family members may seek testing in order to make personal decisions regarding reproduction, financial matters, and career planning. Others may have different motivations including simply the "need to know." Testing of asymptomatic, at-risk, adult family members involves pre-test counseling in which the motives for requesting the test, the individual's knowledge of HDL2, the possible impact of positive and negative test results, and neurologic status are discussed. Those seeking testing should be counseled about possible problems that they may encounter with regard to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Other issues to consider are implications for the at-risk status of other family members, and the limited information available about HDL2. Informed consent should be procured and records kept confidential. Individuals with a positive test result need arrangements for long-term follow-up and evaluations. The best model for HDL2 predictive testing is <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object> predictive testing. Prudence suggests following the same genetic testing guidelines used for Huntington&#x02019;s disease, including counseling prior to testing, a confidant to serve as a social support, and availability of counseling following the disclosure of genetic results.</p>
          <p><bold>Testing of at-risk individuals younger than 18 years of age.</bold> Consensus holds that asymptomatic individuals younger than age 18 years who are at risk for adult-onset disorders should not have testing. The principal arguments against testing asymptomatic individuals during childhood:</p>
          <list list-type="bullet">
            <list-item>
              <p>It removes the individuals choice to know or not know this information.</p>
            </list-item>
            <list-item>
              <p>It raises the possibility of stigmatization within the family and in other social settings.</p>
            </list-item>
            <list-item>
              <p>It could have serious educational and career implications.</p>
            </list-item>
            <list-item>
              <p>No preventive treatment is available for this disorder.</p>
            </list-item>
          </list>
          <p>Individuals younger than 18 years of age who are symptomatic usually benefit from having a specific diagnosis established. </p>
          <p>See also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p><bold>Family planning</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hd-l2.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">JPH3</italic> pathogenic variant has been identified in an affected family member, prenatal diagnosis for pregnancies at increased risk may be available from a laboratory offering testing for this gene or custom prenatal testing.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD</bold>) may be an option for some families in which the pathogenic variant has been identified. </p>
        </sec>
      </sec>
      <sec id="hd-l2.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hd-l2.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Benign allelic variants.</bold> The CTG repeat expansion occurs in a variably spliced exon of <italic toggle="yes">JPH3</italic> denoted as exon 2A [<xref ref-type="bibr" rid="hd-l2.REF.holmes.2001.377">Holmes et al 2001</xref>]. There is now evidence that in humans a transcript from the reverse complementary strand containing the CAG repeat is expressed, but that expression of the transcript and its protein product is low or nonexistent if the repeat is expanded [<xref ref-type="bibr" rid="hd-l2.REF.seixas.2012.245">Seixas et al 2012</xref>]. See <bold>Abnormal gene product</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> The only pathogenic allele detected in <italic toggle="yes">JPH3</italic> to date is the repeat expansion. No attempt has yet been made to find other pathogenic variants in <italic toggle="yes">JPH3</italic>. The longest repeat expansion detected so far is 58 triplets. </p>
        <p><bold>Normal gene product.</bold> The normal full-length <italic toggle="yes">JPH3</italic> product, junctophilin-3, does not include the exon with the repeat [<xref ref-type="bibr" rid="hd-l2.REF.holmes.2001.377">Holmes et al 2001</xref>]. The protein, which is primarily expressed in the brain, appears to help establish the junctional complex between the cytoplasmic membrane and the endoplasmic reticulum (ER). This may serve to link voltage-gated calcium channels with calcium release channels in the ER [<xref ref-type="bibr" rid="hd-l2.REF.nishi.2000.920">Nishi et al 2000</xref>, <xref ref-type="bibr" rid="hd-l2.REF.takeshima.2000.11">Takeshima et al 2000</xref>, <xref ref-type="bibr" rid="hd-l2.REF.ito.2001.1059">Ito et al 2001</xref>]. Exon 2A, containing the repeat, is the terminal exon of a truncated transcript. Because alternate splice acceptor sites occur between exon 1 and exon 2A in this transcript, the repeat may fall into any of three possible reading frames, such that it is in-frame to encode polyalanine, or polyleucine, or it falls in the 3' untranslated region. The pattern of expression and the function of the exon 1 - exon 2A transcript variants are not known, although this short transcript contains the plasma membrane recognition motif, but not the ER insertion domain, present in the full-length transcript.</p>
        <p><bold>Abnormal gene product.</bold> It appears that the repeat expansion results in a decrease in expression of <italic toggle="yes">JPH3</italic> protein product, through sequestration or a loss of expression of the <italic toggle="yes">JPH3</italic> transcript [<xref ref-type="bibr" rid="hd-l2.REF.seixas.2012.245">Seixas et al 2012</xref>]. RNA transcripts with an expanded repeat may have a toxic effect on neurons, similar to the effect of toxic RNA repeat expansions in <related-object link-type="booklink" source-id="gene" document-id="myotonic-d" document-type="chapter">myotonic dystrophy type 1</related-object> and <related-object link-type="booklink" source-id="gene" document-id="myotonic-d2" document-type="chapter">myotonic dystrophy type 2</related-object> [<xref ref-type="bibr" rid="hd-l2.REF.rudnicki.2007.272">Rudnicki et al 2007</xref>]. A mouse model has raised the possibility that a transcript on the reverse complementary strand to <italic toggle="yes">JPH3</italic>, containing the repeat in the CAG orientation, could contribute to disease pathogenesis by encoding a polyglutamine tract [<xref ref-type="bibr" rid="hd-l2.REF.wilburn.2011.427">Wilburn et al 2011</xref>]. As noted above, in humans this antisense transcript can be detected when the repeat is of normal length. However, expression becomes undetectable if the repeat is expanded [<xref ref-type="bibr" rid="hd-l2.REF.seixas.2012.245">Seixas et al 2012</xref>]. </p>
      </sec>
      <sec id="hd-l2.References">
        <title>References</title>
        <sec id="hd-l2.Published_GuidelinesConsensus_Stat">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="hd-l2.Published_GuidelinesConsensus_Stat.reflist0">
            <ref id="hd-l2.REF1">
              <mixed-citation publication-type="webpage">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">online</ext-link>. 2013. Accessed 4-15-15.</mixed-citation>
            </ref>
            <ref id="hd-l2.REF2">
              <mixed-citation publication-type="webpage">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">online</ext-link>. 2012. Accessed 4-15-15.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hd-l2.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hd-l2.Literature_Cited.reflist0">
            <ref id="hd-l2.REF.bates.2002">
              <mixed-citation publication-type="book">Bates G, Harper PS, Jones L, eds. <italic toggle="yes">Huntington's Disease</italic>. Oxford, UK: Oxford University Press; 2002.</mixed-citation>
            </ref>
            <ref id="hd-l2.REF.bauer.2002.662">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gencik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laccone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feder</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weirich</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris-Rosendahl</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolfs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gencikova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wenning</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epplen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riess</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotype.</article-title>
                <source>Ann Neurol</source>
                <volume>51</volume>
                <fpage>662</fpage>
                <pub-id pub-id-type="pmid">12112122</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.holmes.2001.377">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Hearn</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenblatt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callahan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingersoll-Ashworth</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleisher</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potter</surname>
                    <given-names>NT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2.</article-title>
                <source>Nat Genet</source>
                <volume>29</volume>
                <fpage>377</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11694876</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.ito.2001.1059">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komazaki</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitamura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeshima</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Deficiency of triad junction and contraction in mutant skeletal muscle lacking junctophilin type 1.</article-title>
                <source>J Cell Biol</source>
                <volume>154</volume>
                <fpage>1059</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">11535622</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.krause.2002.528s">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Krause</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Temlett</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van der Meyden</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callahan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>CAG/CTG repeat expansions at the HDL2 locus are a common cause of Huntington disease in black South Africans.</article-title>
                <source>Am J Hum Genet</source>
                <volume>71</volume>
                <fpage>528S</fpage>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.margolis.2004.670">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenblatt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gourley</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Hearn</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seltzer</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashizawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayden</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almqvist</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fahn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mysore</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimohata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potter</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakaso</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adachi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakashima</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krause</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenstein</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Huntington's disease-like 2 (HDL2) in North America and Japan.</article-title>
                <source>Ann Neurol</source>
                <volume>56</volume>
                <fpage>670</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15468075</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.margolis.2001.373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Hearn</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenblatt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willour</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franz</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callahan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Troncoso</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.</article-title>
                <source>Ann Neurol.</source>
                <volume>50</volume>
                <fpage>373</fpage>
                <lpage>80</lpage>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.nishi.2000.920">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nishi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizushima</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagawara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeshima</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Characterization of human junctophilin subtype genes.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>273</volume>
                <fpage>920</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10891348</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.rodrigues.2011.419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodrigues</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bader</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danek</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazeneuve</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russaouen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes-Cendes</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marques</surname>
                    <given-names>W</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Tumas</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical and genetic analysis of 29 Brazilian patients with Huntington's disease-like phenotype.</article-title>
                <source>Arq Neuropsiquiatr.</source>
                <volume>69</volume>
                <fpage>419</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">21755114</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.rosenblatt.1998.215">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Rosenblatt</surname><given-names>A</given-names></name><name name-style="western"><surname>Ranen</surname><given-names>NG</given-names></name><name name-style="western"><surname>Rubinsztein</surname><given-names>DC</given-names></name><name name-style="western"><surname>Stine</surname><given-names>OC</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>RL</given-names></name><name name-style="western"><surname>Wagster</surname><given-names>MV</given-names></name><name name-style="western"><surname>Becher</surname><given-names>MW</given-names></name><name name-style="western"><surname>Rosser</surname><given-names>AE</given-names></name><name name-style="western"><surname>Leggo</surname><given-names>J</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>JR</given-names></name></person-group>ffrench-Constant CK, Sherr M, Franz ML, Abbott MH, Ross CA<year>1998</year><article-title>Patients with features similar to Huntington's disease, without CAG expansion in huntingtin.</article-title><source>Neurology</source><volume>51</volume><fpage>215</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">9674805</pub-id></mixed-citation>
            </ref>
            <ref id="hd-l2.REF.ross.1997.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenblatt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranen</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becher</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylward</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA).</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>76</volume>
                <fpage>305</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">9352736</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.rudnicki.2007.272">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rudnicki</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorton</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Huntington&#x02019;s disease-like 2 is associated with CUG repeat containing RNA foci.</article-title>
                <source>Ann Neurol</source>
                <volume>61</volume>
                <fpage>272</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">17387722</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.rudnicki.2008.366">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rudnicki</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pletnikova</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vansattel</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A comparison of Huntington&#x02019;s disease and Huntington&#x02019;s disease-like 2 neuropathology.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>67</volume>
                <fpage>366</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">18379432</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.seixas.2012.245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seixas</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeshima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlovich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachs</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pruitt</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silveira</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnicki</surname>
                    <given-names>DD</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis.</article-title>
                <source>Ann Neurol.</source>
                <volume>71</volume>
                <fpage>245</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">22367996</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.stevanin.2002.965">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camuzat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julien</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sahloul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dode</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn-Barma</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>CAG/CTG repeat expansions at the Huntington's disease-like 2 locus are rare in Huntington's disease patients.</article-title>
                <source>Neurology</source>
                <volume>58</volume>
                <fpage>965</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11914418</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.stevanin.2003.1599">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujigasaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lebre</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camuzat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeannequin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dode</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>San</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellance</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durr</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes.</article-title>
                <source>Brain</source>
                <volume>126</volume>
                <fpage>1599</fpage>
                <lpage>603</lpage>
                <pub-id pub-id-type="pmid">12805114</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.takeshima.2000.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takeshima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komazaki</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kangawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Junctophilins: a novel family of junctional membrane complex proteins.</article-title>
                <source>Mol Cell</source>
                <volume>6</volume>
                <fpage>11</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">10949023</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.walker.2003a.1527">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jankovic</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Hearn</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <year>2003a</year>
                <article-title>Phenotypic features of Huntington's disease-like 2.</article-title>
                <source>Mov Disord</source>
                <volume>18</volume>
                <fpage>1527</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">14673892</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.walker.2002.1031">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgello</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidoff-Feldman</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melnick</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shashidharan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brin</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusions.</article-title>
                <source>Neurology</source>
                <volume>58</volume>
                <fpage>1031</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11940688</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.walker.2003b.1002">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnicki</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alonso</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashizawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidoff-Feldman</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <year>2003b</year>
                <article-title>Huntington's disease-like 2 can present as chorea-acanthocytosis.</article-title>
                <source>Neurology</source>
                <volume>61</volume>
                <fpage>1002</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">14557581</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.wilburn.2011.427">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilburn</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnicki</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitz</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greiner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sopher</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Spada</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osmand</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>YE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>XW</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.</article-title>
                <source>Neuron.</source>
                <volume>70</volume>
                <fpage>427</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">21555070</pub-id>
              </element-citation>
            </ref>
            <ref id="hd-l2.REF.wild.2007.681">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wild</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabrizi</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Huntington's disease phenocopy syndromes.</article-title>
                <source>Curr Opin Neurol.</source>
                <volume>20</volume>
                <fpage>681</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17992089</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hd-l2.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hd-l2.Author_Notes">
          <title>Author Notes</title>
          <p>The laboratory of Dr Russell L Margolis, which identified the first known family with HDL2 and found the causative mutation of HDL2, is actively investigating the phenotype and pathogenesis of HDL2 and welcomes questions about possible HDL2 patients. The laboratory will arrange for free genetic testing for the HDL2 mutation in appropriate patients (DNA, blood, or brain samples). For information, contact Ms. Nadine Yoritomo, 410-955-2398 or <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nyorito1@jhmi.edu">nyorito1@jhmi.edu</email>. Additional information is available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hopkinsmedicine.org/psychiatry/specialty_areas/huntingtons_disease">online</ext-link>.</p>
        </sec>
        <sec id="hd-l2.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 April 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>13 August 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>10 March 2006 (me) Comprehensive update review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>30 January 2004 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>15 September 2003 (rm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
